Conv. Plasma
Nigella Sativa

All vitamin B9 studies
Meta analysis
study COVID-19 treatment researchVitamin B9Vitamin B9 (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs

Hosseini et al., Precision Clinical Medicine, doi:10.1093/pcmedi/pbab001
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
In Silico study identifying novel ligands as potential inhibitors for SARS-CoV-2, including antiemetics rolapitant and ondansetron for Mpro; labetalol and levomefolic acid for PLpro; and leucal and antifungal natamycin for RdRp.
13 preclinical studies support the efficacy of vitamin B9 for COVID-19:
Vitamin B9 has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function EFSA, Galmés, Galmés (B). Vitamin B9 inhibits SARS-CoV-2 In Silico Chen, Eskandari, Hosseini, Kumar, Moatasim, Pandya, Serseg, Ugurel, Zhang, reduces spike protein binding ability Zhang, binds with the spike protein receptor binding domain for alpha and omicron variants Pennisi, inhibits the SARS-CoV-2 nucleocapsid protein Chen, inhibits 3CLpro and PLpro in enzymatic assays Pennisi, significantly reduces infection for alpha and omicron SARS-CoV-2 pseudoviruses Pennisi, and inhibits ACE2 expression and SARS-CoV-2 infection in a mouse model Zhang.
Hosseini et al., 18 Jan 2021, peer-reviewed, 4 authors. Contact:,
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperVitamin B9All
Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs
Maryam Hosseini, Wanqiu Chen, Daliao Xiao, Charles Wang
Precision Clinical Medicine, doi:10.1093/pcmedi/pbab001
The pandemic of novel coronavirus disease 2019 (COVID-19) has rampaged the world, with more than 58.4 million confirmed cases and over 1.38 million deaths across the world by 23 November 2020. There is an urgent need to identify effective drugs and vaccines to fight against the virus. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the family of coronaviruses consisting of four structural and 16 non-structural proteins (NSP). Three non-structural proteins, main protease (Mpro), papain-like protease (PLpro), and RNAdependent RNA polymerase (RdRp), are believed to have a crucial role in replication of the virus. We applied computational ligand-receptor binding modeling and performed comprehensive virtual screening on FDA-approved drugs against these three SARS-CoV-2 proteins using AutoDock Vina, Glide, and rDock. Our computational studies identified six novel ligands as potential inhibitors against SARS-CoV-2, including antiemetics rolapitant and ondansetron for Mpro; labetalol and levomefolic acid for PLpro; and leucal and antifungal natamycin for RdRp. Molecular dynamics simulation confirmed the stability of the ligand-protein complexes. The results of our analysis with some other suggested drugs indicated that chloroquine and hydroxychloroquine had high binding energy (low inhibitory effect) with all three proteins-Mpro, PLpro, and RdRp. In summary, our computational molecular docking approach and virtual screening identified some promising candidate SARS-CoV-2 inhibitors that may be considered for further clinical studies.
Supplementary data Supplementary data are available at PCMEDI online. Conflict of interest statement All authors declared no conflict of interests. In addition, as an Editorial Board Member of Precision Clinical Medicine, the corresponding author Charles Wang was blinded from reviewing and making decision on this manuscript.
Alamri, Altharawi, Alabbas, Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics, Arabian J Chem, doi:10.1016/j.arabjc.2020.08.004
Arul, Kumar, Jeyakanthan, Searching for targetspecific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach, Sci Rep, doi:10.1038/s41598-020-75762-7
Arun, Sharanya, Abhithaj, Drug repurposing to identify therapeutics against COVID 19 with SARS-Cov-2 spike glycoprotein and main protease as targets: an in silico study, ChemRxiv, doi:10.26434/chemrxiv.12090408.v1
Baby, Maity, Mehta, Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19, F1000Research, doi:10.12688/f1000research.26359.1
Baden, Rubin, Covid-19-The Search for Effective Therapy, N Engl J Med, doi:10.1056/NEJMe2005477
Bansal, Zheng, Song, The role of the active site flap in streptavidin/biotin complex formation, J Am Chem Soc, doi:10.1021/jacs.8b00743.
Barretto, Jukneliene, Ratia, The papainlike protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity, J Virol, doi:10.1128/JVI.79.24.15189-15198.2005
Berman, Westbrook, Feng, The Protein Data Bank, Nucleic Acids Res, doi:10.1093/nar/28.1.235
Bhimraj, Morgan, Shumaker, Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19, Clin Infect Dis, doi:10.1093/cid/ciaa478
Brogi, Calderone, Off-target ACE2 ligands: possible therapeutic option for CoVid-19?, Br J Clin Pharmacol, doi:10.1111/bcp.14343
Cao, Wang, Wen, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Ch Ávez Thielemann, Cardellini, Fasano, From GROMACS to LAMMPS: GRO2LAM: A converter for molecular dynamics software, J Mol Model, doi:10.1007/s00894-019-4011-x
Chan, Yao, Yeung, Treatment with Lopinavir/Ritonavir or Interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, J Infect Dis, doi:10.1093/infdis/jiv392
Chang, Tung, Lee, Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking, Preprints, doi:10.20944/preprints202002.0242.v2
Childers, Daggett, Validating molecular dynamics simulations against experimental observables in light of underlying conformational ensembles, J Phys Chem B, doi:10.1021/acs.jpcb.8b02144
Chinnasamy, Selvaraj, Selvaraj, Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2), Int J Biol Macromol, doi:10.1016/j.ijbiomac.2019.12.091
Chu, Cheng, Hung, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, doi:10.1136/thorax.2003.012658
Daczkowski, Dzimianski, Clasman, Structural Insights into the Interaction of Coronavirus Papain-Like Proteases and Interferon-Stimulated Gene Product 15 from Different Species, J Mol Biol, doi:10.1016/j.jmb.2017.04.011
Dey, Borkotoky, Banerjee, In silico identification of Tretinoin as a SARS-CoV-2 Envelope (E) protein ion channel inhibitor, Comput Biol Med, doi:10.1016/j.compbiomed.2020.104063
Friesner, Banks, Murphy, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, J Med Chem, doi:10.1021/jm0306430
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Guo, Cao, Hong, The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status, Mil Med Res, doi:10.1186/s40779-020-00240-0
Gupta, Zhou, Profiling SARS-CoV-2 main protease (MPRO) binding to repurposed drugs using molecular dynamics simulations in classical and neural networktrained force fields, ACS Combinatorial Science, doi:10.1021/acscombsci.0c00140
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet North Am Ed, doi:10.1016/S0140-6736(20)30183-5.
Jin, Du, Xu, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature, doi:10.1038/s41586-020-2223-y
Kar, Potential Anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: A comprehensive review, Viruses, doi:10.3390/v12101092.
Khater, Das, Repurposing Ivermectin to inhibit the activity of SARS CoV2 helicase: possible implications for COVID 19 therapeutics, OSF Preprints, doi:10.31219/
Kim, Won, Kee, Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome, Antivir Ther, doi:10.3851/IMP3002
Kouznetsova, Zhang, Tatineni, Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDAapproved drugs, Peer J, doi:10.7717/peerj.9965
Lamb, Remdesivir: first approval, Drugs, doi:10.1007/s40265-020-01378-w
Lin, Shen, He, Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases, bioRxiv, doi:10.1101/2020.01.31.929695
Liu, Grimm, Dai, CB-Dock: a web server for cavity detection-guided protein-ligand blind docking, Acta Pharmacol Sin, doi:10.1038/s41401-019-0228-6
Liu, Jiang, Liu, Computational Evaluation of the COVID-19 3c-like Protease Inhibition Mechanism, and Drug Repurposing Screening, ChemRxiv, doi:10.26434/chemrxiv.12090426
Liu, Wang, Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines, bioRxiv, doi:10.1016/j.jgg.2020.02.001
Liu, Zheng, Wang, Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224
Martin, Homology models of the papain-like protease PLpro from Coronavirus 2019-nCoV, ChemRxiv, doi:10.26434/chemrxiv.11799705.v1
Martiniano, Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach, J Mol Graph Model, doi:10.1016/j.jmgm.2020.107762
Matthay, Aldrich, Gotts, Treatment for severe acute respiratory distress syndrome from COVID-19, Lancet Respir Med, doi:10.1016/S2213-2600(20)30127-2
Mcconkey, Sobolev, Edelman, The performance of current methods in ligand-protein docking, Curr Sci
Monteleone, Sarzi-Puttini, Ardizzone, Preventing COVID-19-induced pneumonia with anticytokine therapy, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30092-8
Morris, Huey, Lindstrom, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J Comput Chem, doi:10.1002/jcc.21256
Nguyen, Nguyen, Truong, Remdesivir Strongly Binds to both RNA-dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations, J. Phys. Chem. B, doi:10.1021/acs.jpcb.0c07312
Nukoolkarn, Lee, Malaisree, Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors, J Theor Biol, doi:10.1016/j.jtbi.2008.07.030
Nutho, Mahalapbutr, Hengphasatporn, Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019? Atomistic insights into the inhibitory mechanisms, Biochemistry, doi:10.1021/acs.biochem.0c00160
O'boyle, Banck, James, Open Babel: An open chemical toolbox, J Cheminform, doi:10.1186/1758-2946-3-33
Oostenbrink, Villa, Mark, A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6, J Comput Chem, doi:10.1002/jcc.20090
Prajapat, Shekhar, Sarma, Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2, J Mol Graph Model, doi:10.1016/j.jmgm.2020.107716
Rakhshani, Dehghanian, Rahati, Enhanced GROMACS: toward a better numerical simulation framework, J Mol Model, doi:10.1007/s00894-019-4232-z
Ramírez, Caballero, Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data?, Molecules, doi:10.3390/molecules23051038
Refaey, El-Ashrey, Nissan, Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study, Virology, doi:10.1016/j.virol.2020.12.008
Reiner, Hatamipour, Banach, Statins and the COVID-19 main protease, Arch Med Sci, doi:10.5114/aoms.2020.94655
Rimanshee, Amit, Vishal, Potential inhibitors against papain-like protease of novel coronavirus(SARS-CoV-2)from FDA approved drugs, doi:10.26434/chemrxiv.11860011.v2
Rochwerg, Agarwal, Zeng, Remdesivir for severe covid-19: a clinical practice guideline, BMJ, doi:10.1136/bmj.m2924
Rodriguez-Morales, Bonilla-Aldana, Tiwari, COVID-19, an emerging coronavirus infection: current scenario and recent developments-an overview, J Pure Appl Microbiol, doi:10.22207/JPAM.14.1.02
Rothe, Schunk, Sothmann, Transmission of 2019-nCoV infection from an asymptomatic contact in Germany, N Engl J Med, doi:10.1056/NEJMc2001468
Ruiz-Carmona, Alvarez-Garcia, Foloppe, rDock: a fast, versatile and open source program for docking ligands to proteins and nucleic acids, PLoS Comput Biol, doi:10.1371/journal.pcbi.1003571
Snijder, Bredenbeek, Dobbe, Unique and conserved features of genome and proteome of SARScoronavirus, an early split-off from the coronavirus group 2 lineage, J Mol Biol, doi:10.1016/S0022-2836(03)00865-9
Sterling, Irwin, ZINC 15-Ligand discovery for everyone, J Chem Inf Model, doi:10.1021/acs.jcim.5b00559
Trott, Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem, doi:10.1002/jcc.21334
Verity, Okell, Dorigatti, Estimates of the severity of coronavirus disease 2019: a model-based analysis, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30243-7
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Wrapp, Wang, Corbett, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, doi:10.1126/science.abb2507
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B, doi:10.1016/j.apsb.2020.02.008
Wu, Zhao, Yu, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3.
Xu, Peng, Shi, Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation, bioRxiv, doi:10.1101/2020.01.27.92162
Yin, Mao, Luan, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science, doi:10.1126/science.abc1560
Yin, Mao, Luan, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science, doi:10.1126/science.abc1560
Ziebuhr, Siddell, Processing of the human coronavirus 229E replicase polyproteins by the virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to pp1a and pp1ab, J Virol, doi:10.1128/JVI.73.1.177-185.1999
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop